← Human Trials & Peer-Reviewed Studies
Clinical trial on the effects of oral magnesium supplementation in stable-phase COPD patients.
Plain-language guide to PMID 34260036 (2022): double-blind randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 49 participants.
Key Facts
- PMID
- 34260036
- Journal
- Aging clinical and experimental research
- Year
- 2022
- Study type
- Randomized Controlled Trial
- Authors
- Zanforlini BM et al. (10 authors)
- DOI
- 10.1007/s40520-021-01921-z
- Registered trial
- NCT02680769
What This Study Did, in Plain Language
What Was Tested
Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.
The study is registered in clinicaltrial.gov (Trial Registration: NCT02680769, 13 June 2016, retrospectively registered).
Who Took Part
The abstract describes 49 participants taking part.
By PubMed's age tags, the people studied were older adults.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.
Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.
The following parameters were assessed at baseline and after 3 and 6 months: lung function (spirometry), physical performance (handgrip strength, lower limb strength, six-minute walk test), inflammation (e.g., C-reactive protein, CRP), disease-related symptoms, and quality of life (St George's Respiratory Questionnaire, EuroQoL-5D, the Modified British Medical Research Council Questionnaire).
What Was Measured
PubMed files the paper under topics including Dietary Supplements, Disease Progression, Hand Strength, Magnesium, Pulmonary Disease, Chronic Obstructive and Quality of Life.
Author keywords: Chronic obstructive pulmonary disease, Clinical trial and Inflammation.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 49 participants.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2022 (Aging clinical and experimental research), a journal based in Germany.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.